



## UvA-DARE (Digital Academic Repository)

### Coping with cancer and adversity : Hospital ethnography in Kenya

Mulemi, B.A.

**Publication date**  
2010

[Link to publication](#)

#### **Citation for published version (APA):**

Mulemi, B. A. (2010). *Coping with cancer and adversity : Hospital ethnography in Kenya*. African Studies Centre.

#### **General rights**

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

#### **Disclaimer/Complaints regulations**

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

## Appendix 5: Tables

*Table 1* Estimated monthly expenditure (in Ksh) in 'dependent' patients' households

Cases	Medical costs	Other costs	Hospital costs	Total costs	Household income
Mr. Toi	4,100	14,920	12,250	31,770	7,000
Ajwang	3,800	4,900	16,350	25,050	6,500
Mr. Mukuru	6,000	3,000	7,440	16,440	3,000

*Table 2* Estimated monthly expenditure (in Ksh) in households of formally employed and unsalaried breadwinners

Cases	Medical costs	Other costs	Hospital costs	Total costs	Household income
Ms. Souda	7,793	16,746	7,500	32,039	12,000
Mrs Pakot	8,000	17,240	18,150	43,390	6,000
Mr. Jabari	3,100	41,388	8,000	51,988	50,888

Table 3 Cancer drug prices (in Ksh) inside and outside the hospital

Drugs	Hospital	Pharmacy A.	pharmacy B <sup>†</sup>	pharmacy C&D <sup>†</sup>	pharmacy E	Pharmacy F.
Cyclophosphamide 500mg	500	300	350	350; 759	287	----
Cyclophosphamide 200mg	200	200	200	175; 200; 250; 321; 350	200 @40	----
Doxorubicin 50mg	1,000	1,300	1,800	1,620; 1,800; 2,261; 5, 301	1,887	----
Doxorubicin 10mg	200	480	555	495; 550; 779	----	----
Bleomycin 15 IV	1,300	1,400	1,500	2,000; 2,662; 3,450	----	----
Vinblastine 10mg	1,200	1,000	1,150	2,590	----	----
Vincristine 1mg	200	180	150	180; 250; 317	----	----
Methotrexate 50mg	200	180	1,602	380; 400; 650	287	1,600
Actinomycin-D 0.5mg	1,000	400	1,094	1,094	----	----
Etoposide 100mg	900	500	900	900; 2,240; 2,804	1,220	----
Docetaxel 80mg	20,000	18,500	----	18,000; 25,097; 40,000	----	40,000
Docetaxel 20mg	6,000	5,000	----	11,000; 5,400; 7,843	----	11,000
Gemcitabine 200mg	2, 970	----	----	3,295	----	----
Gemcitabine 1gm	14,850	----	----	15,758	----	----
5-Fluorouracil 250mg(5FU)	200	250	300	350; 481; 1000 (Roche)	353	----
Granulocyte colony Stimulating Factor (Neupogen) 300mg 10,071	9,700	(Roche) 11,400	----			
Cisplatin 50mg	500	650	1,100	1,271; 1,458; 1,689; 2,478	1,463	----
Carboplatin 150mg	2,000	1,500	1,700	3,500	----	----
Dacarbazine 200mg	1,680	1,300	1,500	1,800	----	----

Source: Hospital Pharmacy and interviews in selected private pharmacies/ chemists, Nairobi June 2006

<sup>†</sup> Private pharmacy B was a key distributor of anticancer medicines at wholesale prices to all buyers.

<sup>+</sup> From these pharmacies, prices vary as indicated; according to the company supplying the drugs. This was the popular pricing criterion for pharmacies in the central business district and adjacent streets. Most private pharmacists referred to the price guide in a Textbook: Kimotho, J.H. (ed) 2006/2007 (Seventh Edition) *East African Pharmaceutical Loci: A regional drug index for Medical Practitioners*. Nairobi: Pharmaceutical Loci publishers.

*Table 4* Estimated subsidised cost (in Ksh) of some cancer regimes in the ward

Cancer type	Option	Regimen	Cost
Breast cancer	Opt. 1, 1 <sup>st</sup> line	(option 1) 1gm Cyclophosphamide and 80-100gm doxorubicin	3,800
	Opt.2, 1 <sup>st</sup> line	1gm Cyclophosphamide, 100gm methotrexate, 1gm Flourouracil	2,200
	Opt.1 2 <sup>nd</sup> line	1.6gm Gemcetabine and 100gm Cisplatin	25,000
	Opt.2 2 <sup>nd</sup> line	1.6gm Gemcetabine and 450gm carboplatin	30,000
	Opt 3. 2 <sup>nd</sup> line	1000mg doxorubicin and 100gm docetaxel	40,000
Colorectal (colon)	Opt 1	5-Fluorouracil 250 mg (5-FU) and leucovorin	5,500-6,000
Head and neck	Opt. 1	100gm Cisplatin 5-FU-1000mg& radiotherapy	2,000
	Opt 2	5FU, leucovorin	5,500-6,000
Gastric/Stomach		Etoposide 120mg, doxorubicin 20mg, cisplatin 40mg	1,800
Esophageal		5FU 1000mg and cisplatin 75 mg	1,500
Multiple Myeloma		Doxorubicin 50mg, Vincristine 1mg	1,200
Cervical		1mg Vinscristine, cisplatin 50mg, beleomycin 15IV	2,000

Source: Interview with cancer ward pharmacist 2006